BioSpace News Archive

$25M Debt Facility from Deutsche Bank Accelerates Rare Disease Drug Pipeline - Building on Existing Profitable Rare Disease Drug Business

Avacta to make a high performance Affimer research ELISA test available to support global research efforts to combat the coronavirus

Outcomes from the randomized, controlled, open-label REPLACE study included results from 226 patients with pulmonary arterial hypertension (PAH)

Transcenta Holding Limited, a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced the appointment of Dr. Charlie Qi as its Senior Vice President of Global Clinical Development.

Gossamer Bio, Inc. announced that it will present four posters with data relevant to its GB001 and GB002 programs at the Virtual European Respiratory Society International Congress 2020, which takes place from September 7th through 9th.

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

Carbios, a company pioneering new bio-industrial solutions to reinvent the lifecycle of plastic and textile polymers, announced the appointment of Kader Hidra as Chief Financial Officer and member of the Executive Committee of the Company.

Grifols to acquire remaining stock of Alkahest, Inc. in exchange for a total price of $146 million, on a debt-free basis, bringing its ownership of Alkahest to 100%; the transaction is expected to close in early 2021

Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced that the US Food and Drug Administration has granted APG-2575, a novel Bcl-2 inhibitor being developed by the company, an Orphan Drug Designation for the treatment of chronic lymphocytic leukemia.

Midatech Pharma PLC, a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, will be hosting an investor webinar at 2.00pm London time on 10 September 2020, the day of the release of the Company’s interim results for the six months ended 30 June 2020.